Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Grohar

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Molecular Cancer Therapeutics|June 3, 2022
Lurbinectedin Inhibits the EWS-WT1 Transcription Factor in Desmoplastic Small Round Cell TumorJenna M Gedminas, Rebecca Kaufman, Elissa A Boguslawski, et al.
Sarcoma|January 25, 2021
Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology GroupMichael D Kinnaman, Chong Zhu, Daniel A Weiser, et al.
Cancer Chemotherapy and Pharmacology|July 24, 2017
A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcriptPatrick J Grohar, John Glod, Cody J Peer, et al.
Scientific Reports|September 28, 2016
<sup>18</sup>F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing SarcomaChristy L Osgood, Mohammed N Tantawy, Nichole Maloney, et al.
Oncogene|January 16, 2013
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growthC L Yeung, V N Ngo, P J Grohar, et al.
Sarcoma|November 16, 2016
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable ToxicityJ Herzog, F von Klot-Heydenfeldt, S Jabar, et al.
Journal of the National Cancer Institute|June 10, 2011
Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screeningPatrick J Grohar, Girma M Woldemichael, Laurie B Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2019
Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent MannerMatt L Harlow, Maggie H Chasse, Elissa A Boguslawski, et al.
Nature Communications|February 16, 2026
Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcriptionRebecca Kaufman, Guillermo Flores, Elissa A Boguslawski, et al.
Molecular Cancer Therapeutics|March 5, 2020
CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing SarcomaGuillermo Flores, Joel H Everett, Elissa A Boguslawski, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Molecular Cancer Therapeutics|June 3, 2022
Lurbinectedin Inhibits the EWS-WT1 Transcription Factor in Desmoplastic Small Round Cell TumorJenna M Gedminas, Rebecca Kaufman, Elissa A Boguslawski, et al.
Sarcoma|January 25, 2021
Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology GroupMichael D Kinnaman, Chong Zhu, Daniel A Weiser, et al.
Cancer Chemotherapy and Pharmacology|July 24, 2017
A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcriptPatrick J Grohar, John Glod, Cody J Peer, et al.
Scientific Reports|September 28, 2016
<sup>18</sup>F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing SarcomaChristy L Osgood, Mohammed N Tantawy, Nichole Maloney, et al.
Oncogene|January 16, 2013
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growthC L Yeung, V N Ngo, P J Grohar, et al.
Sarcoma|November 16, 2016
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable ToxicityJ Herzog, F von Klot-Heydenfeldt, S Jabar, et al.
Journal of the National Cancer Institute|June 10, 2011
Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screeningPatrick J Grohar, Girma M Woldemichael, Laurie B Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2019
Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent MannerMatt L Harlow, Maggie H Chasse, Elissa A Boguslawski, et al.
Nature Communications|February 16, 2026
Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcriptionRebecca Kaufman, Guillermo Flores, Elissa A Boguslawski, et al.
Molecular Cancer Therapeutics|March 5, 2020
CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing SarcomaGuillermo Flores, Joel H Everett, Elissa A Boguslawski, et al.
Pageof 5